knowledge -WSS

knowledge

author：focus 2025-09-27 13:10:21 - browse：353

PHILADELPHIA — Novo Nordisk, which has dominated the diabetes and obesity markets with its blockbuster drugs Ozempic and Wegovy, now also wants to be a major player in heart disease.

The landmark Select trial presented over the weekend — which showed Wegovy significantly cut the risk of heart complications — is just one of many efforts by the Danish drugmaker to expand into the cardiovascular space. It’s also developing several treatments specific to heart disease and is acquiring a medication for high blood pressure.

“We have a clear vision of being an established cardiovascular company, just as we see ourselves as leaders in diabetes and obesity,” Martin Lange, Novo’s executive vice president of development, said in an interview here at the American Heart Association conference.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： The struggle to figure out which patients 'deserve' Wegovy

WSS

Assistant physicians can help address the primary care shortage

FDA sees ‘potential systemic bias’ in Amgen’s KRAS drug trial

RSV injection headlines need to be accurate for good uptake

The stability of $0 premiums in Medicare Advantage

New oral drug delivery patch is modeled after octopus tentacles

The struggle to figure out which patients 'deserve' Wegovy

Wikipedia

knowledge

focus

Affirmative action in medical school literally saved lives

Information blocking fines are now fair game in health care

Walensky prepares to leave CDC — and Congress — behind

What happened to the House vote on health price transparency?

BioMarin wins approval for gene therapy to treat hemophilia A

What will Novo Nordisk's VC do with its influx of cash?

Peter Hotez and the public health issue of online harassment

Lawsuit highlights wrinkle for disputes over surprise medical bills

Walensky prepares to leave CDC — and Congress — behind

FDA weighs limits of animal data in assessing artificial wombs

hotspot

RSV injection headlines need to be accurate for good uptake

Medicare to pay more for cardiac rehab in hospital outpatient clinics

White House Covid adviser calls on docs to combat misinformation

House panel takes first step toward fixing drug shortages

Patients, doctors press FTC to beef up hospital merger scrutiny

CDC picks Alphabet's Verily for wasterwater surveillance contract

focus

focus

entertainment

hotspot